about
Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis PathwayTo Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory TherapiesGenetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseasesEx vivo response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease.Cytokine levels in the serum of healthy subjectsMevalonate kinase deficiency: disclosing the role of mevalonate pathway modulation in inflammation.Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis.Curcumin and inflammatory bowel disease: potential and limits of innovative treatments.Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage.Alendronate, a double-edged sword acting in the mevalonate pathway.Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency.Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds.Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo.The effect of clodronate on a mevalonate kinase deficiency cellular model.Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line.Temperature and drug treatments in mevalonate kinase deficiency: an ex vivo study.Clinical genetic testing of periodic fever syndromesDefect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes.The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results.Farnesyl and geranylgeranyl transferase inhibitors: an anti-inflammatory effect. Comment to "Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells" Haematologica. 2Inflammatory bowel disease and patterns of volatile organic compounds in the exhaled breath of children: A case-control study using Ion Molecule Reaction-Mass Spectrometry.Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17Mevalonate kinase deficiency and IBD: shared genetic background.Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: in vitro and in vivo approaches.Lovastatin induces apoptosis through the mitochondrial pathway in an undifferentiated SH-SY5Y neuroblastoma cell line.A comparative analysis of serologic parameters and oxidative stress in osteoarthritis and rheumatoid arthritis: reply to Mishra and colleagues.Mouse model of mevalonate kinase deficiency: comparison of cytokine and chemokine profile with that of human patients.Type I interferon-mediated autoinflammation due to DNase II deficiency.TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide.Putative modifier genes in mevalonate kinase deficiency.Neuronal Dysfunction Associated with Cholesterol Deregulation.Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype.Systemic and neuronal inflammatory markers in a mouse model of mevalonate kinase deficiency: a strain-comparative study.Family history in early-onset inflammatory bowel diseasePresence of IL-9 in Paired Samples of Human Colostrum and Transitional MilkSpecific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disordersSerum amyloid A and cholesterol: a pivotal role on inflammationThe Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic DiseasesLetter: inflammatory bowel disease, complementary and alternative medicine, and genetics
P50
Q26771260-1C627F41-A56E-4033-8E70-DD8F0BD6CDE7Q26786973-4DB020A4-010F-40E9-8429-1CEAD6F1F737Q34037058-741A76BD-93C6-4302-B039-76FD60C8D427Q36221213-F0A2CD0C-10EB-4A65-BBEC-E91DAD3B941DQ36711758-C8935EEF-5DE3-41AC-9C1A-2C8C8C204DF6Q38020987-D39CC953-31EB-4991-A5D6-39AF754318DFQ38167274-5E41CBBC-017C-41DE-A132-FDFC9088BFEFQ38292885-8E40DF9C-702A-49F8-B725-DCE04BD9FF08Q38701110-18AAFF76-6048-4826-A48B-E1E5B81A0BCAQ38861481-01437E90-0FC7-4A6E-83A2-460CAEDDDC23Q38871606-76F84185-02A6-41F6-838D-50F0B56E428AQ39001725-915C9536-1142-41A3-B722-C8FDF021490CQ39107997-33EFD780-EE63-426B-AF88-F14D9541AE39Q39304480-1492276F-3D23-4629-B72B-482E024E7C5DQ39320557-A05CE89F-6DB5-4012-A941-0B6F7B9263E1Q39343545-B983F4DA-13DB-40CF-80EE-B3BB0291FCF6Q39452889-F833DB29-CEBC-4FE1-B4E0-2B519E5AFF37Q39525814-4F3DD96D-D9E9-47F4-BFA1-7FAADE1542CEQ39571798-820450C7-4B0A-4076-887F-5830C7E64D2DQ40614943-00F966F0-B352-4903-B470-8B12633FA345Q40892197-FE167D61-32D9-4979-B939-79EB695120C9Q41577330-3FB8B51E-22B9-4080-A6D9-961555FC8561Q41990117-B74CD2AD-B6E4-4AD0-9D1E-0F42843BFEBDQ42751140-BC695AD2-3BEF-444B-95A7-3EA06F5F1B61Q43141414-F42F7D3A-7D79-4408-BD18-07914E02815FQ43180081-273550DA-44AA-4099-B0FB-7AF63BE29987Q45007755-5C588544-99F4-411D-ACD1-B46C661EAD8FQ45892405-56B1735C-A7DA-45A5-A73B-1E162A07A0B1Q47108722-A9E157ED-F245-4B84-8458-1631D6F5DC0FQ47584687-A0DDA0C6-A065-40E4-8877-7CC6B4C5D864Q53158669-2CA9F004-8D0F-4E5E-9A48-613EED83927AQ54108334-5967AF41-6E28-4392-9EC9-CB003BC2A06CQ54274139-833C056E-54C7-45A6-9833-2D60A31CB71EQ54393387-9DD64A42-880E-444B-9967-C764F7255741Q57200143-D376AFC3-A1CA-4D13-8EEF-4998892215C4Q57200146-F192AAC1-0E4A-4E6C-A254-75843EE2881DQ57583802-B87457C6-F2D4-4CDB-B1B6-03D1369BF896Q58251766-38B64A43-1BE5-4943-B629-F436765FC0B0Q60955111-C1082628-13B8-4EE7-9E9F-EB3B7BE425F1Q61451160-11778013-744A-414C-98DD-6990CF67A9F5
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-3427-618X
@en
name
Annalisa Marcuzzi
@ast
Annalisa Marcuzzi
@en
Annalisa Marcuzzi
@es
Annalisa Marcuzzi
@nl
type
label
Annalisa Marcuzzi
@ast
Annalisa Marcuzzi
@en
Annalisa Marcuzzi
@es
Annalisa Marcuzzi
@nl
prefLabel
Annalisa Marcuzzi
@ast
Annalisa Marcuzzi
@en
Annalisa Marcuzzi
@es
Annalisa Marcuzzi
@nl
P106
P31
P496
0000-0003-3427-618X